New Hydrobiome Serum Targets Skin Barrier and Microbiome Balance

Epicutis has announced the launch of Hydrobiome Serum, a new addition to its clinical skincare portfolio developed in partnership with Signum Biosciences. The formulation is designed for patients with blemish-prone or congested skin and emphasizes microbiome balance and barrier support rather than traditional exfoliative or antimicrobial approaches.

Central to the product is TCP, a proprietary ingredient described as a toll-like receptor 2 (TLR2) modulator. According to the company, TCP is intended to regulate inflammatory signaling pathways while maintaining equilibrium within the skin microbiome. This mechanism contrasts with conventional acne-directed therapies that may disrupt microbial diversity or compromise barrier integrity. The serum also incorporates TPNa, a water-soluble derivative of vitamin E, selected for its antioxidant properties and potential role in reinforcing the epidermal barrier. The lightweight formulation is positioned to provide immediate soothing effects alongside longer-term improvements in skin resilience and visible redness. 

The launch aligns with a broader shift toward microbiome-focused skincare, particularly among patients with sensitive skin or those unable to tolerate standard acne treatments. Hydrobiome Serum is currently available for presale through professional channels and is expected to launch nationwide on April 1.

“Hydrobiome Serum represents the next step in our mission to bring biotechnology innovations into dermatology-grade skincare,” said Maxwell Stock, founder and CEO of Epicutis. “By focusing on the biology of skin balance rather than aggressive correction, we’re helping redefine how blemish-prone skin can be supported.”